Abstract: The present invention discloses a novel switchable dual chimeric antigen receptor-T (sdCAR-T) cell and a construction method and use thereof, which fall within the field of cellular immunotherapy for tumors. The dual chimeric antigen receptor consists of a first chimeric antigen receptor for MSLN and a second chimeric antigen receptor for FITC. A dual-targeted functional T cells regulated by specific exogenous bifunctional molecules is constructed, and the exogenous molecules are used to preliminarily discuss the in vivo and in vitro activity of the dual chimeric antigen receptor-T cell. By means of in vitro and in vivo tests, it is confirmed that the activation mode of the constructed CAR-T cell is controlled by the combination of endogenous tumor antigens and exogenous bifunctional molecules, and this combined regulation mode can significantly improve the safe application of CAR-T cell immunotherapy.

Abstract: A polypeptide with analgesic activity and use thereof is disclosed. The polypeptide has the amino acid sequence of Xa-Xb-Cys-Ser-Thr-Pro-Pro-Xc-Xd-Val-Leu-Tyr-Xe (SEQ ID NO: 1), or a pharmaceutically acceptable salt thereof, wherein the Xa is Gly or deleted, the Xb is one of Ser or Lys; the Xc is one of d-Cys or Ser or Asp, the Xd is Ala or deleted; and the Xe is Cys or Ser. One pair of disulfide bonds are formed between two cysteines in the sequence. The polypeptide has good inhibitory effects on physicochemical irritating pain and pathological and neuropathic pain, and has good analgesic effects in various experimental models. The specific effects of the polypeptide are to significantly increase the threshold of pain of mice, prolong the heat tolerance time of mice, and the adverse reactions such as spontaneous movement and excitability of mice are lower than normal values.

Abstract: A polyethylene glycol-modified angiogenesis inhibitor HM-1 and its application are disclosed. The polypeptide sequence is mPEG-Arg-Gly-Ala-Asp-Arg-Ala-Gly-Gly-Gly-Gly-Arg-Gly-Asp (SEQ ID NO: 1), and mPEG . . . is chosen from mPEG-SC, mPEG2-NHS, mPEG-ALD or mPEG-bALD, with a molecular weight range of 500˜40000. The polypeptide has been modified by polyethylene glycol, has the capacity to inhibit vascular endothelial cell migration and integrin affinity and binding, and can be used for the prevention and treatment of tumors, various types of inflammation, and neovascular eye diseases. The polyethylene glycol-modified angiogenesis inhibitor disclosed by the present invention is prepared by a synthetic method.